格隆汇2月26日丨和元生物(688238.SH)公布2025年度业绩快报，报告期内，公司实现营业收入26,766.34 万元，较上年同期增长7.86%；实现归属于母公司所有者的净利润-22,071.57万元，较上年同期减少亏损 10,109.73万元；实现归属于母公司所有者的扣除非经常性损益的净利润-23,202.12万元，较上年同期减 少亏损10,389.12万元。 报告期内，国内生物医药领域机遇与挑战交织并存，呈现出多元化发展与市场激烈竞争的复杂态势，公 司坚持聚焦细胞和基因治疗CRO/CDMO主营业务，并借助国家及行业发展政策，积极战略布局再生医 学应用领域。在运营策略上，公司报告期内侧重点在加强客户资源储备、提升品牌影响力以及推动行业 发展等方面，以练好内功、升级运营管理能力、推动降本增效为主要绩效目标，逐步提升管理质量和运 营效率，为业务后续发展打下坚实基础。 ...

An Road Shanghai 200002 P.R. China 中国上海市延安东路 222 号外滩中心 40 楼 20 Tel/电话:(8621) 6249 6040 Fax/传真:(8621) 6249 5611 Website/网址: www.jinmao.com.cn 上海市金茂律师事务所 关于和元生物技术(上海)股份有限公司 2026年第一次临时股东会之法律意见书 .lin Mao Law Firm H 致:和元生物技术(上海)股份有限公司 和元生物技术（上海）股份有限公司（以下简称"公司"）2026 年第一次临时 股东会〈以下简称"本次股东会"）于 2026年２月 26 日下午在公司会议室召开。 上海市金茂律师事务所（以下简称"本所"）经公司聘请并接受公司委托,委派茅 丽婧律师、赵可沁律师(以下简称"本所律师")出席本次股东会,并根据《中华 人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")、中国证券监督管理委员会公布的《上市公司股东会规则》 (以下简称"《股东会规则》")等相关法律、法规和规范性文件以及《和元生物 技术(上海)股份有限公司章程》 ...

证券代码：688238 证券简称：和元生物 公告编号：2026-005 和元生物技术（上海）股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 26 日 （二） 股东会召开的地点：上海市临港新片区沧海路 3888 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 151 | | --- | --- | | 普通股股东人数 | 151 | | 2、出席会议的股东所持有的表决权数量 | 220,761,415 | | 普通股股东所持有表决权数量 | 220,761,415 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 35.0243 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.0243 | （四） 表决 ...

证券代码：688238 证券简称：和元生物 公告编号：2026-006 和元生物技术（上海）股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以和元生物技术（上海）股份有限公司（以下简称"公司"）2025 年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 26,766.34 | 24,814.92 | 7.86 | | 营业利润 | -21,800.20 | -31,045.08 | 不适用 | | 利润总额 | -21,832.44 | -31,262.71 | 不适用 | | 归属于母公司所有者的净利润 | -22,071.57 | -32,181.30 | 不适用 | | 归属于母公司所有 ...

和元生物公告，公司2025年实现营业收入26,766.34万元，较上年同期增长7.86%；实现归属于母公司所 有者的净利润-22,071.57万元，较上年同期减少亏损10,109.73万元；实现归属于母公司所有者的扣除非 经常性损益的净利润-23,202.12万元，较上年同期减少亏损10,389.12万元。报告期内，国内生物医药领 域机遇与挑战交织并存，呈现出多元化发展与市场激烈竞争的复杂态势，公司坚持聚焦细胞和基因治疗 CRO/CDMO主营业务，并借助国家及行业发展政策，积极战略布局再生医学应用领域。 ...

2月25日，和辉光电大宗交易成交1350万股，成交额3523.5万元，占当日总成交额的17.59%，成交价2.61元，较市场收盘价2.63元折价0.76%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-25 | 和辉光电 | 688238 | 2.61 3523.5 | 1350 | 机构专用 | 国泰海通证券股份 有限公司上海静安 区北京商路 区北京商路 | | ...

Summary of Key Points Core Viewpoint The article discusses the recent developments in China's mother fund industry, highlighting the total management scale of 1161.5 billion yuan, with investments spanning various sectors such as artificial intelligence, new production capacity, and integrated circuits. The article provides insights into fund management recruitment, fund establishment, and LP contributions across different provinces. Fund Management Recruitment - Hebei Province is seeking GP for its Science and Technology Investment Guidance Fund to support strategic and future industries [7] - Sichuan Province is recruiting GP for the Cultural Tourism New Quality Productivity Industry Fund [15] - Chongqing is looking for GP for the Rongchang Mother Fund [17] - Gansu Province is inviting GP for the Jiuquan Science and Technology and Industry Development Fund [20] - Other provinces such as Guangdong, Yunnan, Jiangsu, and Hubei are also actively recruiting GPs for various funds [5][6][43] Fund Establishment - The Jiangsu Super Mother Fund has signed agreements totaling 691 billion yuan, focusing on strategic emerging industries [33][36] - The Yunnan Advanced Manufacturing Equity Investment Mother Fund aims to enhance industrial competitiveness and promote high-quality development [28] - The Shanghai Integrated Circuit Industry Investment Fund has increased its capital to 60.3 billion yuan, marking a significant growth of approximately 1038% [55] LP Contributions - Watson Bio has initiated the establishment of the Yunnan Chuangwo Biological Industry Investment Fund with a target size of 1 billion yuan, contributing 450 million yuan [44] - Jinzhitech plans to invest 240 million yuan to establish an industrial fund in collaboration with local partners [46] - The establishment of the Hohhot Zhongjin Qixin Equity Investment Fund has been announced, with a total investment of 10 billion yuan [51] Other Developments - The establishment of the Ezhou Intelligent Development Equity Investment Fund with a total scale of 30 billion yuan aims to support the AI industry [43] - The Jiangsu Province has successfully registered two industry mother funds with a total scale of 6.5 billion yuan, focusing on smart manufacturing and industrial development [41]

股票简称：和元生物 股票代码：688238 2026 年第一次临时股东会 会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2026 年 2 月 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议资料 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议资料目录 | 2026 年第一次临时股东会会议须知 2 | | | --- | --- | | 2026 年第一次临时股东会会议议程 4 | | | 2026 年第一次临时股东会会议议案 6 | | | 议案一、《关于参与设立产业并购基金暨关联交易的议案》 | 7 | | 议案二、《关于变更公司名称、修订<公司章程>并办理工商变更登记的议案》 | 9 | 1 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议资料 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议须知 为维护广大投资者的合法权益，确保和元生物技术（上海）股份有限公司（以 下简称"公司"或"和元生物"）股东会的正常秩序和议事效率，保障股东在本 次股东会期间依法行使 ...

Core Viewpoint - The article discusses the establishment of a new 500 million RMB industrial merger fund by He Yuan Biotechnology, highlighting the growing trend of merger funds in the Chinese market and the supportive policies driving this growth [2][3][8]. Group 1: Fund Establishment - He Yuan Biotechnology announced its plan to co-establish the He Yuan Hongsheng Industrial Investment Fund with Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. and other partners, with a total fund size of 500 million RMB [5]. - He Yuan Biotechnology will contribute up to 100 million RMB as a limited partner (LP), accounting for 20% of the fund, while the general partners will contribute 5 million RMB, representing 1% [5]. - The fund's duration is set for 8 years, with the first 4 years designated for investment and the latter 4 years for exit [5]. Group 2: Investment Focus - The fund will focus on the cell and gene therapy (CGT) industry chain and related upstream and downstream fields, aiming to provide systematic and efficient tools for industrial integration [6]. - He Yuan Biotechnology aims to leverage Hongsheng Junhao's resources and advantages in equity investment to create a "dedicated strategic platform" around its industrial ecosystem [6]. Group 3: Market Trends - The establishment of this fund reflects a broader trend in the merger fund industry, which has seen significant growth since 2025, driven by supportive policies such as the "New National Nine Articles" and "Merger Six Articles" [8]. - In 2025, 305 listed companies participated in the establishment of 321 industrial merger funds, with a total fundraising scale of approximately 297.51 billion RMB, showing a notable increase from 2024 [8]. - The merger and acquisition (M&A) market is experiencing a surge, with significant transactions across various sectors, including consumer goods, manufacturing, resources, and biomedicine [9]. Group 4: Policy Support - The Chinese government is enhancing support for the merger fund sector, with plans to establish a national-level merger fund and promote innovation and entrepreneurship [10]. - New merger funds are increasingly concentrated in strategic sectors such as advanced manufacturing, healthcare, artificial intelligence, automotive, new materials, and semiconductors, indicating their role in implementing national industrial policies [10]. - In 2025, the transaction volume of China's M&A market exceeded 400 billion USD, marking a 47% year-on-year increase, with expectations for continued activity in high-tech and new energy sectors in 2026 [10].

Group 1 - The core point of the article is that Heyuan Biotechnology (Shanghai) Co., Ltd. has invested 3.35 million RMB to establish Anxing Zhenghe (Changsha) Biotechnology Co., Ltd., holding a 67% stake in the new company [1] - Anxing Zhenghe (Changsha) Biotechnology Co., Ltd. was established on January 5, 2026, with a registered capital of 5 million RMB and is located in Changsha City [1] - The company is involved in various sectors including the production and operation of medical devices, drug import and export, and research and development in cell technology and human stem cell technology [1] Group 2 - The company is authorized to engage in the production of second and third-class medical devices, as well as the rental and sale of medical equipment [1] - It also focuses on technology services, development, consultation, and the sale of hygiene products and disposable medical supplies [1] - The business activities are subject to approval by relevant authorities, and specific operations will commence only after obtaining the necessary permits [1]